Top-Rated StocksTop-RatedNASDAQ:JANX Janux Therapeutics (JANX) Stock Price, News & Analysis $30.68 -0.67 (-2.14%) Closing price 04:00 PM EasternExtended Trading$30.68 +0.00 (+0.02%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Janux Therapeutics Stock (NASDAQ:JANX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Janux Therapeutics alerts:Sign Up Key Stats Today's Range$30.60▼$32.3850-Day Range$29.25▼$57.8152-Week Range$28.92▼$71.71Volume683,143 shsAverage Volume821,287 shsMarket Capitalization$1.81 billionP/E RatioN/ADividend YieldN/APrice Target$92.44Consensus RatingBuy Company OverviewJanux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.Read More… Remove Ads Janux Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks70th Percentile Overall ScoreJANX MarketRank™: Janux Therapeutics scored higher than 70% of companies evaluated by MarketBeat, and ranked 309th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingJanux Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.08, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageJanux Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Janux Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Janux Therapeutics are expected to decrease in the coming year, from ($1.38) to ($2.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Janux Therapeutics is -26.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Janux Therapeutics is -26.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioJanux Therapeutics has a P/B Ratio of 4.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Janux Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted19.05% of the float of Janux Therapeutics has been sold short.Short Interest Ratio / Days to CoverJanux Therapeutics has a short interest ratio ("days to cover") of 8.7.Change versus previous monthShort interest in Janux Therapeutics has recently increased by 3.08%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldJanux Therapeutics does not currently pay a dividend.Dividend GrowthJanux Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted19.05% of the float of Janux Therapeutics has been sold short.Short Interest Ratio / Days to CoverJanux Therapeutics has a short interest ratio ("days to cover") of 8.7.Change versus previous monthShort interest in Janux Therapeutics has recently increased by 3.08%, indicating that investor sentiment is decreasing. News and Social Media2.5 / 5News Sentiment0.58 News SentimentJanux Therapeutics has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Janux Therapeutics this week, compared to 4 articles on an average week.Search Interest6 people have searched for JANX on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Janux Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Company Ownership5.0 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Janux Therapeutics insiders have bought 417.36% more of their company's stock than they have sold. Specifically, they have bought $13,889,565.00 in company stock and sold $2,684,703.00 in company stock.Percentage Held by Insiders29.40% of the stock of Janux Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions75.39% of the stock of Janux Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Janux Therapeutics' insider trading history. Receive JANX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Janux Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address JANX Stock News HeadlinesJanux Therapeutics, Inc. (NASDAQ:JANX) Insider Andrew Hollman Meyer Sells 3,334 SharesMarch 6, 2025 | insidertrades.comJanux Therapeutics (JANX) Expected to Announce Earnings on FridayMarch 12 at 1:58 AM | americanbankingnews.comEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… They’re studying something far more alien… Something you’ve never seen before…March 14, 2025 | Paradigm Press (Ad)Janux Therapeutics (NASDAQ:JANX) Shares Gap Up on Insider Buying ActivityMarch 12 at 1:15 AM | americanbankingnews.comInsiders Are Loading Up on These 4 Biotech Stocks NowMarch 11 at 8:45 AM | 247wallst.comJanux Therapeutics, Inc. (NASDAQ:JANX) Receives $88.00 Consensus Price Target from AnalystsMarch 9, 2025 | americanbankingnews.comJANUX THERAPEUTICS Earnings Preview: Recent $JANX Insider Trading, Hedge Fund Activity, and MoreMarch 7, 2025 | nasdaq.comHC Wainwright Has Pessimistic Outlook of JANX Q1 EarningsMarch 7, 2025 | americanbankingnews.comSee More Headlines JANX Stock Analysis - Frequently Asked Questions How have JANX shares performed this year? Janux Therapeutics' stock was trading at $53.54 on January 1st, 2025. Since then, JANX shares have decreased by 42.4% and is now trading at $30.8130. View the best growth stocks for 2025 here. How were Janux Therapeutics' earnings last quarter? Janux Therapeutics, Inc. (NASDAQ:JANX) released its earnings results on Thursday, February, 27th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative trailing twelve-month return on equity of 10.47% and a negative net margin of 463.91%. When did Janux Therapeutics IPO? Janux Therapeutics (JANX) raised $152 million in an IPO on Friday, June 11th 2021. The company issued 9,500,000 shares at $15.00-$17.00 per share. BofA Securities, Cowen and Evercore ISI acted as the underwriters for the IPO and H.C. Wainwright & Co. LLC was co-manager. Who are Janux Therapeutics' major shareholders? Top institutional investors of Janux Therapeutics include RA Capital Management L.P. (19.75%), FMR LLC (16.52%), Janus Henderson Group PLC (6.79%) and Paradigm Biocapital Advisors LP (6.70%). Insiders that own company stock include Ra Capital Management, LP, Tighe Reardon, David Alan Campbell, Andrew Hollman Meyer and Ventures Xi LP Avalon. View institutional ownership trends. How do I buy shares of Janux Therapeutics? Shares of JANX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Janux Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Janux Therapeutics investors own include American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC), Voyager Therapeutics (VYGR), Waste Connections (WCN) and AUO (AUOTY). Company Calendar Last Earnings2/27/2025Today3/14/2025Next Earnings (Estimated)3/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:JANX CIK1817713 Webwww.januxrx.com Phone858-751-4493FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Stock Price Target$92.44 High Stock Price Target$200.00 Low Stock Price Target$41.00 Potential Upside/Downside+194.9%Consensus RatingBuy Rating Score (0-4)3.08 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($1.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-58,290,000.00 Net Margins-463.91% Pretax Margin-463.91% Return on Equity-10.47% Return on Assets-9.86% Debt Debt-to-Equity RatioN/A Current Ratio38.80 Quick Ratio38.80 Sales & Book Value Annual Sales$10.59 million Price / Sales175.00 Cash FlowN/A Price / Cash FlowN/A Book Value$7.46 per share Price / Book4.20Miscellaneous Outstanding Shares59,105,000Free Float37,052,000Market Cap$1.85 billion OptionableOptionable Beta3.23 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:JANX) was last updated on 3/14/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredElon’s desperate gambleWarning: "DOGE Collapse" Imminent After months of cost-cutting, controversy, and media buzz, DOGE is on the...Altimetry | SponsoredTrump’s new tariffs could break China’s grip on manufacturingLooming trade wars have China scrambling… Over 90% of global corporate executives said they are shutting do...Weiss Ratings | SponsoredIs 2025 really the best time to get rich in American history?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump's 100-Day Plan Triggers Global RetaliationIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredMarch 18th: Gold SHOCK?Starting March 18th, a major shift could send gold soaring — or crashing. Either way this shift goes... ...InvestorPlace | SponsoredSomething strange is happening in Virginia…In this urgent exposé, you’ll discover… How Elon and Donald Trump are quietly drawing a radical new map of ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Janux Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Janux Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.